Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aarhus University Hospital, Mølleparkvej 10, PO Box 210, DK-9100 Aalborg, Denmark.
Schizophr Bull. 2012 May;38(3):592-8. doi: 10.1093/schbul/sbq137. Epub 2010 Nov 26.
Constipation is a known side effect of psychotropics that possess high affinity for muscarinic cholinergic receptors. In severe cases, constipation progresses to ileus and bowel ischemia, with multiple fatalities related to sepsis and perforation described in the literature, primarily among patients with schizophrenia. A historical prospective database study was performed using registry data from psychiatric and somatic hospitals, combined with the prescription database to examine associations between medications and ileus. Only cases with an ICD-10 diagnosis of schizophrenia (F20) and a concurrent diagnosis of ileus in the years 1996-2007 were included in the study. A total of 26,720 patients with schizophrenia were identified with 123 cases of ileus noted in the study period. Increasing age (OR: 1.03 CI: 1.01-1.04) and female sex (OR: 1.60 CI: 1.10-2.31) were associated with an increased risk of ileus. Treatment with clozapine (OR: 1.99 CI: 1.21-3.29), high-potency first-generation antipsychotics (OR: 1.81 CI: 1.01-3.23), tricyclic antidepressants (OR: 2.29 CI: 1.29-4.09), anticholinergics (OR: 1.48 CI: 1.00-2.19), and opioids (OR: 2.14 CI: 1.36-3.36) were associated with an increased risk of ileus. The onset of ileus occurred on average more than 3 years after the first prescription of the offending drug. Aripiprazole and amisulpride were not associated with ileus. Nine of the ileus cases (7.3%) had a fatal course. Treatment with clozapine (OR: 6.73 CI: 1.55-29.17) or anticholinergics (OR: 5.88 CI: 1.47-23.58) were associated with increased risk of fatal ileus. Patients receiving psychotropics associated with significant anticholinergic properties should undergo proper monitoring and interventions in order to minimize the burden of constipation and the risk of ileus.
便秘是具有高亲和力毒蕈碱型乙酰胆碱能受体的精神类药物的已知副作用。在严重的情况下,便秘会发展为肠梗阻和肠缺血,文献中描述了与败血症和穿孔相关的多例死亡,主要发生在精神分裂症患者中。本研究使用来自精神科和躯体医院的登记数据以及处方数据库进行了一项历史性前瞻性数据库研究,以检查药物与肠梗阻之间的关联。只有在 1996 年至 2007 年期间 ICD-10 诊断为精神分裂症(F20)且同时伴有肠梗阻诊断的患者才被纳入研究。共确定了 26720 例精神分裂症患者,在研究期间有 123 例肠梗阻病例。年龄增长(OR:1.03,95%CI:1.01-1.04)和女性(OR:1.60,95%CI:1.10-2.31)与肠梗阻风险增加相关。氯氮平(OR:1.99,95%CI:1.21-3.29)、高效第一代抗精神病药物(OR:1.81,95%CI:1.01-3.23)、三环类抗抑郁药(OR:2.29,95%CI:1.29-4.09)、抗胆碱能药物(OR:1.48,95%CI:1.00-2.19)和阿片类药物(OR:2.14,95%CI:1.36-3.36)与肠梗阻风险增加相关。肠梗阻的发病平均在首次使用致病药物 3 年以上。阿立哌唑和氨磺必利与肠梗阻无关。9 例肠梗阻病例(7.3%)的病程为致命性。氯氮平(OR:6.73,95%CI:1.55-29.17)或抗胆碱能药物(OR:5.88,95%CI:1.47-23.58)的治疗与致命性肠梗阻的风险增加相关。接受具有显著抗胆碱能特性的精神类药物治疗的患者应接受适当的监测和干预,以最大程度地减轻便秘的负担和肠梗阻的风险。